Home Online Features FDA Expands the Age Indication for Nerivio® as the First-and-Only REN Wearable for Migraine Treatment for Children Aged Eight and Above
FDA Expands the Age Indication for Nerivio® as the First-and-Only REN Wearable for Migraine Treatment for Children Aged Eight and Above
Press Releases
Theranica  
November 14, 2024

FDA Expands the Age Indication for Nerivio® as the First-and-Only REN Wearable for Migraine Treatment for Children Aged Eight and Above

Children aged eight and up now have a prescribed non-drug option to treat migraine early and potentially prevent long-term disability and disease progression, addressing a critical unmet need in pediatric

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social